C56 - Multiple Sclerosis Therapy: Disease-modifying Treatment I
| Event Time: | Sunday May 5, 2019 1:00 pm to 3:00 pm |
| Topic(s): | MS and CNS Inflammatory Disease, Advanced Practice Provider |
| Director(s): | Scott Newsome DO, FAAN |
| Description: | The use of disease-modifying treatments (DMTs) in MS is one of the most rapidly evolving therapeutic areas in neurology. As new and arguably more effective treatments have become available, decision-making in regard to MS DMTs has become much more complex for both neurologists and people with MS. This course will review the mechanisms of action and the risk-benefit ratios of the DMTs and delve into different treatment paradigms, risk mitigation strategies, sequencing considerations, and shared decision-making. This program complements Multiple Sclerosis Therapy: Disease-modifying Treatment II, but covers independent topics. |
| Completion Message: | Participants should be familiar with the indications and risks associated with approved disease-modifying agents in multiple sclerosis, and be better able to identify the appropriate patient populations for the newer agents. |
| CME Credits: | 2 |
| Core Competencies: | Patient Care, Medical Knowledge |
| Start/End Time | Title | Faculty |
|---|---|---|
| 1:00 PM - 2:00 PM | A Brave New World of MS Therapeutics | Scott Douglas Newsome DO, FAAN |
| 2:00 PM - 2:45 PM | MS Treatment Paradigms, Risk Mitigation, and Sequencing Considerations | Gabriel Pardo MD, FAAN |
| 2:45 PM - 3:00 PM | Questions and Answers | Faculty |
| Speaker | Disclosure |
|---|---|
| Scott Douglas Newsome, DO, FAAN | Dr. Newsome has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Celgene, EMD Serono, Genentech, medDay Pharmaceuticals, and Gerson Lehrman Group.. Dr. Newsome has received research support from Biogen, Genentech, Department of Defense, the National MS Society, and Patient-Centered Outcomes Research Institute. |
| Gabriel Pardo, MD, FAAN | Dr. Pardo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Biogen, Celgene, EMD Serono, Roche/Genentech, Novartis, and Sanofi Genzyme. |
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 7:00 AM-9:00 AM |
|---|
|
C247 -
What Do I Do Now?: Emergency and Inpatient Management of Migraine and Other Headache Disorders
Stephanie Nahas MD, FAAN |
|
C248 -
Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making
Aaron Miller MD, FAAN |
| 9:15 AM-11:30 AM |
|
Neurology Year in Review Plenary Session
Martinson Arnan MD |
| 1:00 PM-3:00 PM |
|
S56 -
MS Trials and Treatment
|
| 3:30 PM-4:30 PM |
|
C257 -
Education Blitz: Evolution of Autoimmune Neurology
Steven Vernino MD, PhD, FAAN |
|
C258 -
Education Blitz: Multiple Sclerosis
Stephen Krieger MD, FAAN |